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2Abstract  
Background: IGF-I immunoassays are primarily used to estimate IGF-I bioactivity. Recently, an IGF-
I specific Kinase Receptor Activation Assay (KIRA) has been developed as an alternative method. 
However, no normative values have been established for the IGF-I KIRA. 
Objective: To establish normative values for the IGF-I KIRA in healthy adults. 
Design: Cross-sectional study in healthy non-fasting blood donors.  
Study participants: 426 healthy individuals (310 M, 116 F; age range: 18 – 79 yrs)
Main outcome Measures: IGF-I bioactivity determined by the KIRA. Results were compared with 
total IGF-I, measured by five different IGF-I immunoassays.  
Results: Mean (± SD) IGF-I bioactivity was 423 (± 131) pmol/L and decreased with age (β = -3.4 
pmol/L/yr, p < 0.001). In subjects younger than 55 yrs mean IGF-I bioactivity was significantly higher 
in women than in men. Above this age this relationship was inverse, suggesting a drop in IGF-I 
bioactivity after menopause. This drop was not reflected in total IGF-I levels. IGF-I bioactivity was 
significantly related to total IGF-I (rs varied between 0.46 – 0.52; P-values < 0.001).  
Conclusions: We established age-specific normative values for the IGF-I KIRA. We observed a 
significant drop in IGF-I bioactivity in women between 50 and 60 years, which was not perceived by 
IGF-I immunoassays. The IGF-I KIRA, when compared to IGF-I immunoassays, theoretically has the 
advantage that it measures net effects of IGF-binding proteins on IGF-I receptor activation. However, 
it has to be proven whether information obtained by the IGF-I KIRA is clinically more relevant than 
measurements obtained by IGF-I immunoassays.
3Introduction 
Fifty years ago Salmon and Daughaday 
discovered a factor in serum which stimulated 
sulphate incorporation by cartilage in vitro (1). 
This unknown factor, then called sulphation 
factor or somatomedin-C, was later renamed 
insulin-like growth factor-I (IGF-I) (2, 3). 
After generation of highly specific antibodies 
for IGF-I, it became possible to develop 
immunoassays for the assessment of 
circulating IGF-I levels (4-6). Today, these 
IGF-I immunoassays are clinically widely used 
to assess IGF-I bioactivity in humans and are 
applicable to measure large numbers of blood 
samples.
In the circulation about 99% of circulating 
IGF-I is bound to six high affinity IGF-binding 
proteins (IGFBPs) (7). IGFBPs interfere with 
antibody binding to IGF-I and therefore, in 
virtually all common IGF-I immunoassays an 
extraction method has to be used in order to 
remove these IGFBPs (8, 9). Remaining 
IGFBPs or their fragments may interfere and 
produce falsely increased or decreased 
circulating total IGF-I levels (10). This latter 
phenomenon may especially occur in 
pathological conditions (11).  
Another problem is that large differences in 
absolute circulating levels of total IGF-I are 
observed between different commercially 
available IGF-I immunoassays (8, 12). 
Recently it was suggested that this variability 
in assay performance and the use of 
inappropriate reference ranges undermine the 
applicability of international consensus criteria 
in local practice (11). Nevertheless, 
introduction of IGF-I immunoassays has been 
proven to be useful in the diagnosis and 
treatment of acromegaly (13). 
The IGFBPs are considered to regulate IGF-I 
bioavailability (7, 14). However, the 
commonly used IGF-I immunoassays in fact 
ignore the effects of IGFBPs on the 
interactions between IGF-I and the IGF-I 
receptor (10). Frystyk et al. recently developed 
a kinase receptor activation assay (KIRA) 
specific for IGF-I (15, 16). This IGF-I KIRA 
quantifies phosphorylation of tyrosine residues 
of the activated IGF-I receptor (IGF-IR) as a 
measure for IGF-I bioactivity in serum (17). In 
contrast to commonly used IGF-I 
immunoassays, the IGF-I KIRA is sensitive for 
modifications of IGF-IR activation by 
circulating IGFBPs and IGFBP-proteases (15, 
18). Therefore, the IGF-I KIRA method might 
be an important advancement in measuring 
circulating IGF-I bioactivity, which could 
enhance insights in the IGF-I system both in 
normal and pathological conditions.  
The aim of the present study was to establish 
normative values for the IGF-I KIRA in the 
healthy population. Results of the IGF-I KIRA 
were compared with circulating total IGF-I 
levels obtained by five commonly used IGF-I 
immunoassays (19). 
Research Design and Methods 
Subjects and measurements 
The study population has been described 
previously (19). Briefly, morning serum 
samples were taken from healthy non-fasting 
blood donors (N = 426; females N = 116). Age 
ranged from 18 to 79 years (median: 44 yrs). 
Height and weight were measured and the 
body mass index (BMI) was calculated. Mean 
± SD for BMI was 25.3 ± 3.9 kg/m2
 (range: 
15.8 – 42.2). All participants gave informed 
consent. The Ethics Committee of the Charité 
Humboldt University (Berlin, Germany) had 
approved this study.  
Total IGF-I Immunoassays 
Five different immunoassays were used to 
measure total circulating IGF-I in the healthy 
population. Three of these assays were 
immunometric assays, whereas two were 
conventional radioimmunoassays (RIAs). The 
following immunoassays were used: Assay A: 
IGF-I RIA, an in-house assay at University 
Children’s Hospital, Tuebingen, Germany; 
Assay B: IGF-I RIA-CTTM, Mediagnost, 
Tuebingen, Germany; Assay C: Diagnostic 
Systems Laboratories (DSL) 2800 Active®
IGF-I-IRMA, Sinsheim, Germany; Assay D: 
Nichols Advantage® Chemiluminiscence IGF-I 
Immunometric assay, Nichols Institute 
Diagnostics, San Juan Capistrano, CA, USA.; 
Assay E: IGF-I CIA, Immulite®, Diagnostic 
Products Corp. (DPC). In all immunoassays 
recombinant human IGF-I was used as 
standard. After acidification an excess of IGF-
II was used to eliminate residual interference 
with IGFBPs. For four of these immunoassays 
4(Assays 1, 2, 3 and 4), the age-related 
reference ranges for circulating total IGF-I in 
this study population have been previously 
published (19). Intra- (a) and inter- (b) assay 
coefficients of variation varied between (a) 3.1 
− 7.0% and (b) 3.8 − 8.8% respectively (19).  
Total IGF-I levels are expressed as nmol/L (to 
convert total IGF-I levels into μg/L, values 
have to be divided by 0.131).  
IGF-I Kinase receptor activation assay (IGF-
I KIRA) 
Circulating IGF-I bioactivity was measured 
using an in-house IGF-I kinase receptor 
activation assay as was previously described 
(15). This assay uses human embryonic renal 
cells stably transfected with cDNA of the 
human IGF-IR gene (293 EBNA IGF-IR). 
Cells were a kind gift from Prof. Pierre de 
Meyts, (Receptor Biology Laboratory, 
Hagedorn Research Institute, Novo Nordisk, 
Gentofte, Denmark). After 48 ours of culture, 
cells were stimulated at 37°C with either 
recombinant IGF-I standards (Austral 
Biologicals, San Ramon, CA) or 10-fold 
diluted serum samples for 15 minutes and 
lysed afterwards. Crude lysates were 
transferred to a sandwich assay. For capture a 
monoclonal antibody directed against the 
human IGF-IR (MAD1, 1μg/well, Gropep, 
Adelaide, Australia) was used. As tracer a 
europium-labelled monoclonal anti-
phosphotyrosine antibody (PY20, Perkin-
Elmer Life Sciences) was used. Contents were 
read in a time-resolved fluorometer (Victor2
multilabel counter, Perkin-Elmer, Groningen, 
The Netherlands). Assays were performed in 
48 well plates. IGF-I standards, 2 control 
samples, and unknown serum samples were 
included in duplicate on every plate. Intra-
assay CV was 5.6%. The inter-assay CVs were 
respectively 6.8% and 12.6% for the two 
control samples, which averaged (mean ± SD) 
414 ± 28 pmol/L and 1146 ± 144 pmol/L (N = 
60 plates), respectively. Circulating IGF-I 
bioactivity is expressed as pmol/L (to convert 
IGF-I bioactivity into μg/L, values have to be 
divided by 131). Serum samples used in the 
IGF-I KIRA were kept at -80°C and had been 
thawed ones. From previous unpublished data 
we know that repetitive freezing and thawing 
of serum samples (up to several times) does 
not change results of the IGF-I KIRA. IGF-I 
KIRA measurements were performed 5 years 
after initial collection of serum. 
Statistical Analysis 
Data were analyzed using SPSS for Windows, 
release 12.0 (SPSS, Chicago, Illinois) unless 
otherwise reported. For IGF-I bioactivity 
measurements means ± SD, medians, and the 
95% confidence intervals (95% CI) are 
presented. The Kolmogorov-Smirnov test with 
the Dallal-Wilkinson-Lilliefors correction (K-S 
test) and the D′Agustino and Pearson omnibus 
test (A-P test: GraphPad version 5.0, GraphPad 
Software, Inc., San Diego) were used to test 
data for normality of distribution. When no 
normality of distribution was found, data were 
log-transformed. Correlations between IGF-I 
bioactivity and total IGF-I are presented as 
Spearman correlation coefficients (rs). 
Nonparametric Mann-Whitney or Wilcoxon 
rank sum tests were used to compare IGF-I 
levels between men and women categorized by 
age. Linear regression was used to calculate 
the relationship between IGF-I bioactivity and 
age. The coefficient of variation (CV) was 
calculated by using the formula: (SD/mean) 
×100%. This CV standardizes the relative 
spread in data between IGF-I assays, so that a 
sensible comparison can be made. Curve 
estimation and regression analysis were 
performed to determine whether age-related 
changes were best fitted by a linear, 
exponential or polynomial function. Where 
more than one function was significant, the 
one with the highest R2 value was considered 
the best fitting model. A P value < 0.05 was 
considered statistically significant.  
Results 
Circulating IGF-I bioactivity was almost 
normally distributed (untransformed data: K-S 
test; p = 0.07, A-P test; p = 0.04, (Figure 1A)). 
Log-transformation of IGF-I bioactivity levels 
did not improve normality of the data 
distribution (log-transformed data: K-S test; p 
= 0.0001, A-P test; p < 0.0001). In contrast, 
circulating total IGF-I levels showed an 
asymmetric distribution in all five studied IGF-
I immunoassays (untransformed data: K-S and 
5A-P tests; p < 0.0001 for all immunoassays 
(Figure 1B – 1F)). After log-transformation of 
total IGF-I levels a normal distribution (K-S 
and A-P test: p > 0.05) was obtained in three 
out of five IGF-I immunoassays (data not 
shown). (Total IGF-I assays that did not show 
a normal distribution after log transformation 
were: DSL IGF-I IRMA (K-S test; p = 0.003, 
A-P test; p = 0.005) and Nichols IGF-I CIA 
(K-S test; p = 0.03 and A-P test; p = 0.02). 
Linear correlation and regression coefficients 
between the measurements of IGF-I 
immunoassays are shown in Table 1. 
To estimate the spread in the data of IGF-I in 
the study population, we calculated the 
coefficient of variation (CV).  The CV for the 
IGF-I KIRA was 31% and thereby lower than 
for the five studied IGF-I immunoassays 
(Mediagnost IGF-I RIA: 34%, In-house IGF-I 
RIA: 36%, DPC IGF-I CIA: 42%, Nichols 
IGF-I CIA: 45%, DSL IGF-I IRMA: 48%, 
respectively).  
Mean (± SD) circulating IGF-I bioactivity was 
423 (± 131) pmol/L and ranged from 57 to 875 
pmol/L. In Table 2 mean values of circulating 
IGF-I bioactivity are presented after 
stratification for age. IGF-I bioactivity 
decreased significantly with age, which was 
best fitted by a linear model (slope β = -3.4 
pmol/L/yr, (95% CI: -4.5 – -2.5); p < 0.001). 
There was no significant difference in β (p = 
0.16) between men (β = -2.9 pmol/L/yr (95% 
CI: -3.8 – -1.9); p < 0.0001) and women (β = -
4.6 pmol/L/yr (95% CI: -6.0 – -3.3); p < 0.001) 
(Figure 2)).  With one exception (Nichols), the 
age-related decreases in total IGF-I were best 
fitted by polynomial (quadratic) functions 
(data not shown). The decrease of total IGF-I 
with age measured by the total IGF-I CIA 
(Nichols) was best fitted by a linear model (β = 
-0.48 nmol/L/yr, (95% CI: -0.54 – -0.42); p < 
0.001). 
Overall, there were no gender specific 
differences in mean IGF-I bioactivity (men: 
mean = 420 pmol/L, (95% CI: 405 – 435) vs.
women: mean = 433 (95% CI: 409 – 458); p = 
0.36 (adjusted for age and BMI)). 
In subjects younger than 55 yrs, mean IGF-I 
bioactivity was significantly higher in women 
than in men (men (N = 207) mean = 436 
pmol/L, (95% CI: 418 – 454) vs. (women (N = 
76): mean = 484 (95% CI: 455 – 513); p = 
0.007, (Figure 3)). Above the age of 55 years 
this relationship was opposite and mean IGF-I 
bioactivity in women was significantly lower 
than in men (men (N = 103) mean = 387 
pmol/L, (95% CI: 366 – 408) vs. women (N = 
40): mean 337 (95% CI: 313 – 361); p = 
0.008).  In all five IGF-I immunoassays there 
were no gender-specific differences in mean 
circulating total IGF-I levels before age 55 yrs 
(data not shown). Above age 55 years mean 
circulating total IGF-I levels were significantly 
lower in women than in men in all IGF-I 
immunoassays (data not shown). The 
statistically significant drop in IGF-I 
bioactivity in women around age 55 years was 
not observed for all five IGF-I immunoassays. 
Circulating IGF-I bioactivity was significantly 
related to circulating total IGF-I levels (rs
varied between 0.46 – 0.52, p < 0.001 for all 
five IGF-I immunoassays, Figure 4A – 4E). 
Mean circulating IGF-I bioactivity calculated 
as percentage of total IGF-I averaged 1.8 to 
2.4% (in-house RIA: 2.4% (0.42 – 5.82) 
(median (range)), Mediagnost: 2.2% (0.34 – 
5.2), DSL: 2.3% (0.33 – 9.1), Nichols: 1.8% 
(0.32 – 5.88) and DPC: 1.8% (0.29 – 5.38). 
This calculated bioactive IGF-I fraction 
increased significantly with age for all five 
IGF-I immunoassays (β varied between 
0.010% – 0.033% per year; p < 0.001 for all). 
IGF-I bioactivity was not related to height, 
weight or BMI, whereas total IGF-I levels 
were positively related to height (r varied 
between 0.17 – 0.23, p < 0.003 for all), and 
negatively to BMI (rs varied between - 0.24 
and -0.20, p < 0.001 for all).                              
Discussion
To our knowledge this is the first study that 
reports age-specific normative ranges of 
circulating IGF-I bioactivity in the healthy 
population obtained by the IGF-I KIRA. These 
normative values are based on measurements 
in more than 400 normal subjects with age 
ranging from 18 – 79 yrs. These age-specific 
normative ranges will be helpful to interpret 
whether IGF-I bioactivity is normal, increased 
and/or decreased in subjects with pathological 
conditions like acromegaly and GH deficiency.  
Currently used IGF-I immunoassays have 
indeed yielded important and biologically 
meaningful information about the IGF-I 
system (20). However, many problems have 
been reported when IGF-I immunoassays were 
6used in clinical practice (13). Attempts to 
resolve these problems have focused on 
methods of separating IGF-I from its binding 
proteins (IGFBPs) prior to IGF-I 
measurements. Although there have been 
many technologies developed to eliminate 
interference of IGFBPs, in many IGF-I 
immunoassays, remaining IGFBPs or BP 
fragments may still interfere and produce 
falsely increased or decreased circulating total 
IGF-I levels (21). This latter effect may 
especially be of importance in 
pathophysiologic states accompanied by 
significant changes in IGFBP levels, such as 
diabetes mellitus and renal failure (21). For 
example, Chestnut and Quarmby showed that 
while the correlation between IGF-I 
immunoassays was high in sera of healthy 
individuals, there was a lack of correlation 
between immunoassays when sera from 
individuals with diabetes were analysed (8).  
IGF-I immunoassays only determine the 
immunoreactive properties of the IGF-I 
molecule, rather than its actual biological 
effect (22). The separation of IGF-I from the 
IGFBPs prior to the IGF-I measurements 
ignores in fact the important modulating 
effects of IGFBPs on IGF-I bioavailability. 
However, clinicians are generally interested in 
the biological effects of IGF-I (22).  
An important reason for using IGF-I 
immunoassays has been the lack of reliable 
IGF-I bioassays (10, 16). Previous IGF-I 
bioassays were based on downstream 
signalling events (e.g. sulphate incorporation 
by cartilage, cell proliferation and survival), 
but they often suffered from high variability 
and long assay duration (16, 23, 24). 
Moreover, these IGF-I bioassays often had a 
lack of specificity and were labour-intensive. 
An ideal assay for assessing IGF-I bioactivity 
should be easily quantifiable, highly sensitive 
and based on a signal specifically transmitted 
by the IGF-IR (25).  In this respect, the IGF-I 
KIRA comes close to an ideal IGF-I bioassay 
as it directly targets the activated IGF-IR, 
requires only small volumes of serum, has a 
short incubation time, is sensitive to the 
modifying influences of circulating IGFBPs 
and IGFBP-proteases and has an overall 
precision that is fully comparable to the 
traditional IGF-I immunoassays (15, 16, 18). 
However, the KIRA is still more labour-
intensive than immunoassays. In addition, we 
realize that IGF-I KIRA measurements were 
performed with serum and therefore obtained 
results do not necessarily reflect net IGF-I 
bioactivity present in the extra-vascular 
tissues.  
Interestingly, IGF-I immunoassays that did not 
utilize removal of IGFBPs have been described 
previously in literature (5). These older assays 
for IGF-I were not considered useful for 
clinical practice, as it was assumed that IGFBP 
interference was a priori bad for determination 
of IGF-I (9).  However, this opens the 
possibility that the results of these older IGF-I 
assays might correlate better with IGF-I KIRA 
results than do modern IGF-I immunoassays, 
which prior to its measurement extract IGF-I 
from IGFBPs.  
Circulating IGF-I bioactivity showed a wide 
inter-individual variability among subjects in 
every age group. The CV of the IGF-I KIRA 
within the study population (a standardized 
measure of relative spread in data) was lower 
than that for total IGF-I. Since a lower 
magnitude of CV is considered to reflect a 
better reliability (precision) of measurements, 
this suggests that the IGF-I KIRA in this 
respect performs at least equal to IGF-I 
immunoassays. 
IGF-I bioactivity was positively related to total 
IGF-I in all studied IGF-I immunoassays. 
Interestingly, for all IGF-I immunoassays the 
observed correlation coefficients were 
relatively low and comparable. Our results 
show that the observed relation between total 
IGF-I and IGF-I bioactivity is independent of 
the type of immunoassay that is used to 
determine circulating total IGF-I levels. In 
addition, these results suggest that the IGF-I 
KIRA produces new information about the 
IGF-I system, which differs from that obtained 
by IGF-I immunoassays. However, the 
physiological importance of this difference 
remains to be clarified. 
Circulating IGF-I bioactivity decreased 
significantly with age. The decline of IGF-I 
bioactivity with age was less steep than that 
observed for circulating total IGF-I levels. As 
a consequence the mean calculated fraction of 
IGF-I bioactivity over total IGF-I increased 
slightly but significantly with age. Although 
the cross-sectional study design does not 
reflect the intra-individual rate of change of 
IGF-I bioactivity, a possible explanation for 
7this latter observation is that IGF-I bioactivity 
becomes less-GH dependent with aging than 
total IGF-I levels. Another explanation could 
be that the relative increase in IGF-I 
bioactivity with age reflects a compensatory 
mechanism to overcome an age-dependent 
relative IGF-IR resistance. Third, also 
circulating IGF-II levels could be involved. In 
contrast to IGF-I, circulating levels of IGF-II 
do not decrease after puberty but remain stable 
throughout life (26). Chen et al. showed that 
the 293 EBNA IGF-IR cells respond not only 
to IGF-I but also to IGF-II, which has a cross-
reactivity of 12%, to the IGF-I KIRA 
compared to IGF-I (15). This opens the 
possibility that the relative contribution of 
IGF-II to the IGF-I KIRA signal increases with 
aging.   
Remarkably, before age 55 years of age, the 
mean IGF-I bioactivity was significantly 
higher in women than in men, while after this 
age an inverse relationship was observed. This 
significant drop in IGF-I bioactivity in women 
between the age of 50 and 60 years was not 
reflected in total IGF-I levels. Although we do 
not have information about age of menopause 
in the studied women, we speculate that the 
observed decrease in IGF-I bioactivity after 
age 55 years of age is related to changes in 
estrogens levels (27-29). This could explain 
why women had a relatively higher mean IGF-
I bioactivity than men before 55 years, but also 
why mean IGF-I bioactivity was lower in 
women than in men after this age.  
In conclusion, in the present study we 
established age-specific normative values for 
circulating IGF-I bioactivity levels in the 
healthy adult population. The IGF-I KIRA 
produces new information about the circulating 
IGF-I system that differs from that obtained by 
IGF-I immunoassays. Whether this 
information is clinically more relevant than 
measurement of circulating total IGF-I levels 
in the diagnosis and/or treatment of GH 
disorders is at present unclear. However, the 
establishment of these normative reference 
values for IGF-I bioactivity is the first step to 
answer these questions in the near future. 
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Figure legends 
Figure 1: Distribution of IGF-I measurements in the study population: A) IGF-I KIRA; B) IGF-I RIA, 
an in-house assay at University Children’s Hospital, Tuebingen, Germany; C) IGF-I RIA-CTTM, 
Mediagnost; D) IGF-I-IRMA 2800 Active®, DSL; E) IGF-I CIA, Nichols Advantage®; F) IGF-I CIA, 
Immulite® DPC. Data obtained by the IGF-I KIRA showed an almost normal distribution, in contrast 
to IGF-I immunoassays for which data were skewed leftwards. An ideal bell-shaped normal 
distribution curve is shown in each plot. 
Figure.2: IGF-I bioactivity levels according to age. IGF-I bioactivity decreased significantly with age 
in both men () and women (•).  Linear regression lines for men (       ) and women (       ) are shown.
Figure 3: Mean circulating IGF-I bioactivity according to age categories and sex. Mean circulating 
IGF-I bioactivity levels in women (     ) differed significantly from men (      ), being higher in age 
groups 35-44 years (p = 0.04), and 45-54 years (p = 0.008) and lower in age group 55-64 years (p = 
0.009). Between 50 and 60 years of age there was a drop in mean circulating IGF-I bioactivity in 
women. Overall, before 55 years of age circulating IGF-I bioactivity in women was significantly 
higher, and after this age significantly lower when compared to men. Data are presented as mean ±
SEM. *Significant difference between men and women within an age category. **Significant 
difference between men and women before or after age 55 years.
Figure 4: Relations between circulating IGF-I bioactivity measured by the IGF-I KIRA vs. circulating 
total IGF-I measured by five different IGF-I immunoassays to measure total IGF-I: A) IGF-I RIA, an 
in-house assay at University Children’s Hospital, Tuebingen, Germany; B) IGF-I RIA-CTTM, 
Mediagnost; C) IGF-I-IRMA 2800 Active®, DSL; D) IGF-I CIA, Nichols Advantage®; E) IGF-I CIA, 
Immulite® DPC. 
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Table 1: Linear regression equations: comparison of the relation between five IGF-I immunoassays. 
Independent variable (X) Dependent  
variable(Y) 
A B C D 
A  ***    
B R2
Y 
= 0.85 
= 2.20x + 0.97 
***   
C R2
Y 
= 0.85 
= 1.43x – 5.38 
R2
Y 
= 0.80 
= 1.32x – 5.58 
***  
D R2
Y 
= 0.82 
= 1.52x – 3.20 
R2
Y 
= 0.75 
= 1.37x – 2.96 
R2
Y 
= 0.87 
= 1.01x + 3.54 
*** 
E R2
Y 
= 0.87 
= 1.45x – 2.60 
R2
Y 
= 0.91 
= 1.41x – 4.19 
R2
Y 
= 0.86 
= 0.93x + 4.57 
R2
Y 
= 0.81 
= 0.84 + 3.36 
Regression models are based on total IGF-I levels expressed as nmol/L. In all models correlation was significant 
(P < 0.001 for all). IGF-I immunoassays: A) IGF-I RIA, an in-house assay at University Children’s Hospital, 
Tuebingen, Germany; B) IGF-I RIA-CTTM, Mediagnost; C) IGF-I-IRMA 2800 Active®, DSL; D) IGF-I CIA, 
Nichols Advantage®; E) IGF-I CIA, Immulite® DPC.
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Table 2: Age-related reference ranges for IGF-I bioactivity in healthy adults (N = 426) 
Age 
(years) 
Number  
(N) 
Female  
(N) 
Mean 
(pmol/L) 
SD 
(pmol/L) 
Median 
(pmol/L) 
95% CI  
(pmol/L) 
< 24 38 7 527 139 528 (481 - 573) 
25 - 34 66 20 476 140 461 (441 - 510) 
35 - 44 100 30 432 132 428 (406 - 459) 
45 - 54 79 19 411 122 402 (384 - 438) 
55 - 64 103 24 385 108 383 (363 - 405) 
> 65 40 16 344 081 343 (318 - 370) 
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